Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Rigel Appoints Michael P. Miller to the Board of Directors PR Newswire - Tue Feb 3, 7:05AM CST

SOUTH SAN FRANCISCO, Calif. , Feb. 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller...

RIGL : 34.54 (+0.94%)
Rigel Provides Business Update and 2026 Outlook PR Newswire - Mon Jan 12, 7:05AM CST

SOUTH SAN FRANCISCO, Calif. , Jan. 12, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 34.54 (+0.94%)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire - Fri Jan 9, 7:05AM CST

SOUTH SAN FRANCISCO, Calif. , Jan. 9, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc....

RIGL : 34.54 (+0.94%)
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire - Wed Jan 7, 7:05AM CST

SOUTH SAN FRANCISCO, Calif. , Jan. 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 34.54 (+0.94%)
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition PR Newswire - Sun Dec 7, 2025

SOUTH SAN FRANCISCO, Calif. , Dec. 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 34.54 (+0.94%)
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference PR Newswire - Wed Nov 26, 2025

SOUTH SAN FRANCISCO, Calif. , Nov. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 34.54 (+0.94%)
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology PR Newswire - Mon Nov 17, 2025

SOUTH SAN FRANCISCO, Calif. , Nov. 17, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 34.54 (+0.94%)
Rigel to Present at the Jefferies Global Healthcare Conference in London PR Newswire - Wed Nov 12, 2025

SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 34.54 (+0.94%)
Rigel: Q3 Earnings Snapshot AP - Tue Nov 4, 2025

Rigel: Q3 Earnings Snapshot

RIGL : 34.54 (+0.94%)
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update PR Newswire - Tue Nov 4, 2025

SOUTH SAN FRANCISCO, Calif. , Nov. 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 34.54 (+0.94%)

Barchart Exclusives

1 Dividend Stock Yielding 4.7% and Trading at 10-Year Highs Barchart - 11 minutes ago
DHT Holdings (DHT) is trading at a new 15-year high. Shares are up 41% over the past 52 weeks. DHT trade is expected to grow revenue and earnings growth and pays a dividend yielding a generous 4.7% yield. Analyst sentiment is robust with multiple “Strong Buy” ratings and price targets... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot